Treatment of Moderate-to-severe Atopic Dermatitis with Upadacitinib: Results from an Interim Analysis of the TREATgermany Registry

Werfel T, Heratizadeh A, Aberer W, Augustin M, Biedermann T, Bauer A, et al. S3 guideline Atopic dermatitis: Part 2 - Systemic treatment. J Dtsch Dermatol Ges 2024; 22: 307–320.

https://doi.org/10.1111/ddg.15229 DOI: https://doi.org/10.1111/ddg.15229

Simpson EL, Papp KA, Blauvelt A, Chu CY, Hong HC, Katoh N, et al. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the measure up 1 and measure up 2 randomized clinical trials. JAMA Dermatol 2022; 158: 404–413.

https://doi.org/10.1001/jamadermatol.2022.0029 DOI: https://doi.org/10.1001/jamadermatol.2022.0029

Silverberg JI, Guttman-Yassky E, Simpson EL, Papp KA, Blauvelt A, Chu C-Y, et al. 502 - Efficacy and safety of upadacitinib through 140 weeks in adolescents and adults with moderate-to-severe atopic dermatitis: phase 3 randomized clinical trial results. Br J Dermatol 2024; 190: ii8–ii.

https://doi.org/10.1093/bjd/ljad498.010 DOI: https://doi.org/10.1093/bjd/ljad498.010

Taylor PC, Laedermann C, Alten R, Feist E, Choy E, Haladyj E, et al. A JAK inhibitor for treatment of rheumatoid arthritis: the baricitinib experience. J Clin Med 2023; 12: 4527.

https://doi.org/10.3390/jcm12134527 DOI: https://doi.org/10.3390/jcm12134527

Lancet Gastroenterology H. New restrictions on JAK inhibitors in the EU. Lancet Gastroenterol Hepatol 2023; 8: 1.

https://doi.org/10.1016/S2468-1253(22)00397-1 DOI: https://doi.org/10.1016/S2468-1253(22)00397-1

Guttman-Yassky E, Thyssen JP, Silverberg JI, Papp KA, Paller AS, Weidinger S, et al. Safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis of phase 3 studies. J Allergy Clin Immunol 2023; 151: 172–181.

https://doi.org/10.1016/j.jaci.2022.09.023 DOI: https://doi.org/10.1016/j.jaci.2022.09.023

Schlösser AR, Boeijink N, Olydam J, Nijsten TEC, Hijnen D. Upadacitinib treatment in a real-world difficult-to-treat atopic dermatitis patient cohort. J Eur Acad Dermatol Venereol 2024; 38: 384–392.

https://doi.org/10.1111/jdv.19581 DOI: https://doi.org/10.1111/jdv.19581

Gargiulo L, Ibba L, Bianco M, Di Giulio S, Alfano A, Cascio Ingurgio R, et al. Upadacitinib 30 mg for the optimal management of moderate-to-severe atopic dermatitis: a 52-week single-center real-world study. J Dermatolog Treat 2024; 35: 2375102.

https://doi.org/10.1080/09546634.2024.2375102 DOI: https://doi.org/10.1080/09546634.2024.2375102

Siegels D, Haufe E, Heinrich L, Werfel T, Weidinger S, Schmitt J, et al. Status report on the atopic dermatitis registry TREATgermany. Allergol Select 2021; 5: 274–286.

https://doi.org/10.5414/ALX02262E DOI: https://doi.org/10.5414/ALX02262E

Heratizadeh A, Haufe E, Stölzl D, Abraham S, Heinrich L, Kleinheinz A, et al. Baseline characteristics, disease severity and treatment history of patients with atopic dermatitis included in the German AD Registry TREATgermany. J Eur Acad Dermatol Venereol 2020; 34: 1263–1272.

https://doi.org/10.1111/jdv.16078 DOI: https://doi.org/10.1111/jdv.16078

Traidl S, Heinrich L, Siegels D, Heratizadeh A, Kind B, Haufe E, et al. Treatment of moderate-to-severe atopic dermatitis with baricitinib: results from an interim analysis of the TREATgermany registry. J Eur Acad Dermatol Venereol 2024; 38: e887–e891.

https://doi.org/10.1111/jdv.19979 DOI: https://doi.org/10.1111/jdv.19979

Risk of serious adverse effects with Janus kinase inhibitors. Drug Ther Bull 2023; 61: 35.

https://doi.org/10.1136/dtb.2022.000078 DOI: https://doi.org/10.1136/dtb.2022.000078

Gargiulo L, Ibba L, Piscazzi F, Amoruso F, Balato A, Barei F, et al. Upadacitinib improves symptoms of concomitant allergic rhinitis or allergic asthma in patients with severe atopic dermatitis: a 16-week multicentre retrospective study. J Eur Acad Dermatol Venereol 2024; 38: e743–e6.

https://doi.org/10.1111/jdv.19862 DOI: https://doi.org/10.1111/jdv.19862

Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 2022; 386: 316–326.

https://doi.org/10.1056/NEJMoa2109927 DOI: https://doi.org/10.1056/NEJMoa2109927

Yoon S, Kim K, Shin K, Kim HS, Kim B, Kim MB, et al. The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol 2024; 38: 52–61.

https://doi.org/10.1111/jdv.19426 DOI: https://doi.org/10.1111/jdv.19426